Targeting cancer with epi-drugs: A precision medicine perspective

Current Pharmaceutical Biotechnology

Volumn 17, Issue 10, 2016, Pages 856-865

  Gherardini, Lisa ^a   Sharma, Ankush ^b   Capobianco, Enrico ^b,c   Cinti, Caterina ^a  

^a Institute of Clinical Physiology   (Italy)

^b CNR   (Italy)

^c UNIVERSITY OF MIAMI   (United States)

Author keywords

Cancer epigenomics; Cancer therapy; Epi drugs; Epigenetic memory; Precision medicine; Translational medicine

Indexed keywords

2 DEOXY 5 AZACYTIDINE (3 5) 2 DEOXYGUANOSINE SODIUM; AZACITIDINE; BELINOSTAT; CAS 9 PROTEIN; CELLULAR APOPTOSIS SUSCEPTIBILITY PROTEIN; DECITABINE; DNA METHYLTRANSFERASE INHIBITOR; GIVINOSTAT; HISTONE DEACETYLASE INHIBITOR; PACLITAXEL; PANOBINOSTAT; PROTEIN E6; PROTEIN E7; ROMIDEPSIN; ST7612AA1; TRANSCRIPTION ACTIVATOR LIKE EFFECTOR NUCLEASE; UNCLASSIFIED DRUG; VEMURAFENIB; VORINOSTAT; ZINC FINGER NUCLEASE; ANTINEOPLASTIC AGENT;

ARTICLE; CANCER GENE THERAPY; CARCINOGENESIS; CHROMATIN IMMUNOPRECIPITATION; CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEAT; DNA DAMAGE; DNA METHYLATION; EPIGENETICS; GENE EXPRESSION; HIGH THROUGHPUT SEQUENCING; HISTONE ACETYLATION; HUMAN; LONG INTERSPERSED REPEAT; NONHUMAN; PERSONALIZED MEDICINE; SHORT INTERSPERSED REPEAT; CHEMOPROPHYLAXIS; GENETIC EPIGENESIS; NEOPLASMS; PHYSIOLOGY; PROCEDURES;

ANTINEOPLASTIC AGENTS; CHEMOPREVENTION; DNA METHYLATION; EPIGENESIS, GENETIC; HUMANS; NEOPLASMS; PRECISION MEDICINE;

EID: 84978272015     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/1381612822666160527154757     Document Type: Article

References (69)

1. Fraga, M.F.; Ballestar, E.; Paz, M.F.; Ropero, S.; Setien, F.; Ballestar, M.L.; Heine-Suner, D.; Cigudosa, J.C.; Urioste, M.; Benitez, J.; Boix-Chornet, M.; Sanchez-Aguilera, A.; Ling, C.; Carlsson, E.; Poulsen, P.; Vaag, A.; Stephan, Z.; Spector, T.D.; Wu, Y.Z.; Plass, C.; Esteller, M. Epigenetic differences arise during the lifetime of monozygotic twins. Proc. Natl. Acad. Sci. USA, 2005, 102, 10604-10609.
2. Peedicayil, J. The role of DNA methylation in the pathogenesis and treatment of cancer. Curr. Clin. Pharmacol., 2012, 7, 333-340.
3. Chun, P. Histone deacetylase inhibitors in hematological malignancies and solid tumors. Arch. Pharm. Res., 2015, 38, 933-949.
4. Yao, Y.; Des Marais, T.L.; Costa, M. Chromatin memory in the development of human cancers. Gene Technol., 2014, 3, 114.
5. Ehrlich, M.; Lacey, M. DNA hypomethylation and hemimethylation in cancer. Adv. Exp. Med. Biol., 2013, 754, 31-56.
6. Plass, C.; Pfister, S.M.; Lindroth, A.M.; Bogatyrova, O.; Claus, R.; Lichter, P. Mutations in regulators of the epigenome and their connections to global chromatin patterns in cancer. Nat. Rev. Genet., 2013, 14, 765-780.
7. Malecova, B.; Morris, K.V. Transcriptional gene silencing through epigenetic changes mediated by non-coding RNAs. Curr. Opin. Mol. Ther., 2010, 12, 214-222.
8. Caudron-Herger, M.; Rippe, K. Nuclear architecture by RNA. Curr. Opin. Genet. Dev., 2012, 22, 179-187.
9. Caudron-Herger, M.; Muller-Ott, K.; Mallm, J.P.; Marth, C.; Schmidt, U.; Fejes-Toth, K.; Rippe, K. Coding RNAs with a noncoding function: Maintenance of open chromatin structure. Nucleus, 2011, 2, 410-424.
10. Lai, F.; Shiekhattar, R. Enhancer RNAs: The new molecules of transcription. Curr. Opin. Genet. Dev., 2014, 25, 38-42.
11. Orom, U.A.; Shiekhattar, R. Noncoding RNAs and enhancers: Complications of a long-distance relationship. Trends Genet., 2011, 27, 433-439.
12. Khan, D.H.; Jahan, S.; Davie, J.R. Pre-mRNA splicing: Role of epigenetics and implications in disease. Adv. Biol. Regul., 2012, 52, 377-388.
13. Guil, S.; Esteller, M. Cis-acting noncoding RNAs: Friends and foes. Nat. Struct. Mol. Biol., 2012, 19, 1068-1075.
14. Cheedipudi, S.; Genolet, O.; Dobreva, G. Epigenetic inheritance of cell fates during embryonic development. Front Genet., 2014, 5, 19.
15. Youngson, N.A.; Whitelaw, E. Transgenerational epigenetic effects. Annu. Rev. Genomics Hum. Genet., 2008, 9, 233-257.
16. Halley-Stott, R.P.; Gurdon, J.B. Epigenetic memory in the context of nuclear reprogramming and cancer. Br. Funct. Genomics, 2013, 12, 164-173.
17. Xu, D.; Bai, J.; Duan, Q.; Costa, M.; Dai, W. Covalent modifications of histones during mitosis and meiosis. Cell Cycle, 2009, 8, 3688-3694.
18. Roberti, A.; La Sala, D.; Cinti, C. Multiple genetic and epigenetic interacting mechanisms contribute to clonally selection of drugresistant tumors: Current views and new therapeutic prospective. J. Cell Physiol., 2006, 207, 571-581.
19. Monk, M.; Holding, C. Human embryonic genes re-expressed in cancer cells. Oncogene, 2001, 20, 8085-8091.
20. Kim, J.; Woo, A.J.; Chu, J.; Snow, J.W.; Fujiwara, Y.; Kim, C.G.; Cantor, A.B.; Orkin, S.H. A Myc network accounts for similarities between embryonic stem and cancer cell transcription programs. Cell, 2010, 143, 313-324.
21. Ben-Porath, I.; Thomson, M.W.; Carey, V.J.; Ge, R.; Bell, G.W.; Regev, A.; Weinberg, R.A. An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat. Genet., 2008, 40, 499-507.
22. Tam, W.L.; Weinberg, R.A. The epigenetics of epithelialmesenchymal plasticity in cancer. Nat. Med., 2013, 19, 1438-1449.
23. Shen, H.; Laird, P.W. Interplay between the cancer genome and epigenome. Cell, 2013, 153, 38-55.
24. Varley, K.E.; Gertz, J.; Bowling, K.M.; Parker, S.L.; Reddy, T.E.; Pauli-Behn, F.; Cross, M.K.; Williams, B.A.; Stamatoyannopoulos, J.A.; Crawford, G.E.; Absher, D.M.; Wold, B.J.; Myers, R.M. Dynamic DNA methylation across diverse human cell lines and tissues. Genome Res., 2013, 23, 555-567.
25. El Baroudi, M.; La Sala, D.; Cinti, C.; Capobianco, E. Pathway landscapes and epigenetic regulation in breast cancer and melanoma cell lines. Theor. Biol. Med. Model., 2014, 11(1), 8.
26. Mora, A.; Taranta, M.; Zaki, N.; Badidi, E.; Cinti, C.; Capobianco, E. Ensemble inference by integrative cancer networks. Front. Genet., 2014, 5, 59.
27. Witte, T.; Plass, C.; Gerhauser, C. Pan-cancer patterns of DNA methylation. Genome Med., 2014, 6, 66.
28. Sandhu, R.; Rivenbark, A.G.; Coleman, W.B. Enhancement of chemotherapeutic efficacy in hypermethylator breast cancer cells through targeted and pharmacologic inhibition of DNMT3b. Breast Cancer Res. Treat., 2012, 131, 385-399.
29. Foltz, G.; Yoon, J.G.; Lee, H.; Ryken, T.C.; Sibenaller, Z.; Ehrich, M.; Hood, L.; Madan, A. DNA methyltransferase-mediated transcriptional silencing in malignant glioma: A combined wholegenome microarray and promoter array analysis. Oncogene, 2009, 28, 2667-2677.
30. Swierczynski, S.; Klieser, E.; Illig, R.; Alinger-Scharinger, B.; Kiesslich, T.; Neureiter, D. Histone deacetylation meets miRNA: Epigenetics and post-transcriptional regulation in cancer and chronic diseases. Expert Opin. Biol. Ther., 2015, 15, 651-664.
31. Kim, H.S.; Shen, Q.; Nam, S.W. Histone Deacetylases and Their Regulatory MicroRNAs in Hepatocarcinogenesis. J. Korean Med. Sci., 2015, 30, 1375-1380.
32. Medina-Franco, J.L.; Yoo, J. Docking of a novel DNA methyltransferase inhibitor identified from high-throughput screening: Insights to unveil inhibitors in chemical databases. Mol. Divers., 2013, 17, 337-344.
33. Thomas, X. DNA methyltransferase inhibitors in acute myeloid leukemia: Discovery, design and first therapeutic experiences. Expert Opin. Drug Discov., 2012, 7, 1039-1051.
34. Yoo, J.; Kim, J.H.; Robertson, K.D.; Medina-Franco, J.L. Molecular modeling of inhibitors of human DNA methyltransferase with a crystal structure: Discovery of a novel DNMT1 inhibitor. Adv. Protein Chem. Struct. Biol., 2012, 87, 219-247.
35. Pettersen, E.F.; Goddard, T.D.; Huang, C.C.; Couch, G.S.; Greenblatt, D.M.; Meng, E.C.; Ferrin, T.E. UCSF Chimera--a visualization system for exploratory research and analysis. J. Comput. Chem., 2004, 25, 1605-1612.
36. Pan, D.; Mao, C.; Zou, T.; Yao, A.Y.; Cooper, M.P.; Boyartchuk, V.; Wang, Y.-X. The histone demethylase JHDM1a regulates hepatic gluconeogenesis. PLoS Genet., 2012, 8, 1002761.
37. Lapierre, L.R.; Kumsta, C.; Sandri, M.; Ballabio, A.; Hansen, M. Transcriptional and epigenetic regulation of autophagy in aging. Autophagy, 2015, 11, 867-880.
38. Gallinari, P.; Di Marco, S.; Jones, P.; Pallaoro, M.; Steinkühler, C. HDACs, histone deacetylation and gene transcription: From molecular biology to cancer therapeutics. Cell Res., 2007, 17, 195-211.
39. Lee, J.Y.-C.; Kuo, C.-W.; Tsai, S.-L.; Cheng, S.M.; Chen, S.-H.; Chan, H.-H.; Lin, C.-H.; Lin, K.-Y.; Li, C.-F.; Kanwar, J.R.; Leung, E.Y.; Cheung, C.C.H.; Huang, W.-J.; Wang, Y.-C.; Cheung, C.H.A. Inhibition of HDAC3- and HDAC6-promoted survivin expression plays an important role in saha-induced autophagy and viability reduction in breast cancer cells. Front. Pharmacol., 2016, 7, 81.
40. Lauffer, B.E.L.; Mintzer, R.; Fong, R.; Mukund, S.; Tam, C.; Zilberleyb, I.; Flicke, B.; Ritscher, A.; Fedorowicz, G.; Vallero, R.; Ortwine, D.F.; Gunzner, J.; Modrusan, Z.; Neumann, L.; Koth, C.M.; Lupardus, P.J.; Kaminker, J.S.; Heise, C.E.; Steiner, P. Histone Deacetylase (HDAC) inhibitor kinetic rate constants correlate with cellular histone acetylation but not transcription and cell viability. J. Biol. Chem., 2013, 288, 26926-26943.
41. Mottamal, M.; Zheng, S.; Huang, T.L.; Wang, G. Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents. Molecules, 2015, 20, 3898-3941.
42. Coral, S.; Parisi, G.; Nicolay, H.J.; Colizzi, F.; Danielli, R.; Fratta, E.; Covre, A.; Taverna, P.; Sigalotti, L.; Maio, M. Immunomodulatory activity of SGI-110, a 5-Aza-2’-deoxycytidinecontaining demethylating dinucleotide. Cancer Immunol. Immunother., 2013, 62, 605-614.
43. Kuang, Y.; El-Khoueiry, A.; Taverna, P.; Ljungman, M.; Neamati, N. Guadecitabine (SGI-110) priming sensitizes hepatocellular carcinoma cells to oxaliplatin. Mol. Oncol., 2015, 9, 1799-1814.
44. Vesci, L.; Bernasconi, E.; Milazzo, F.M.; De Santis, R.; Gaudio, E.; Kwee, I.; Rinaldi, A.; Pace, S.; Carollo, V.; Giannini, G.; Bertoni, F. Preclinical antitumor activity of ST7612AA1: A new oral thiol-based histone deacetylase (HDAC) inhibitor. Oncotarget, 2015, 6, 5735-5748.
45. Huang, Y.-C.; Huang, F.-I.; Mehndiratta, S.; Lai, S.-C.; Liou, J.-P.; Yang, C.-R. Anticancer activity of MPT0G157, a derivative of indolylbenzenesulfonamide, inhibits tumor growth and angiogenesis. Oncotarget, 2015, 6, 18590-18601.
46. Cramer, S.A.; Adjei, I.M.; Labhasetwar, V. Advancements in the delivery of epigenetic drugs. Expert Opin. Drug Deliv., 2015, 12, 1501-1512.
47. Liu, S. Epigenetics advancing personalized nanomedicine in cancer therapy. Adv. Drug Deliv. Rev., 2012, 64, 1532-1543.
48. Gandhi, N.S.; Tekade, R.K.; Chougule, M.B. Nanocarrier mediated delivery of sirna/mirna in combination with chemotherapeutic agents for cancer therapy: Current progress and advances. J. Control Release, 2014, 194, 238-256.
49. Wu, F.L.; Li, R.T.; Yang, M.; Yue, G.F.; Wang, H.Y.; Liu, Q.; Cui, F.B.; Wu, P.Y.; Ding, H.; Yu, L.X.; Qian, X.P.; Liu, B.R. Gelatinases-stimuli nanoparticles encapsulating 5-fluorouridine and 5-aza-2’-deoxycytidine enhance the sensitivity of gastric cancer cells to chemical therapeutics. Cancer Lett., 2015, 363, 7-16.
50. Li, S.Y.; Sun, R.; Wang, H.X.; Shen, S.; Liu, Y.; Du, X.J.; Zhu, Y.H.; Jun, W. Combination therapy with epigenetic-targeted and chemotherapeutic drugs delivered by nanoparticles to enhance the chemotherapy response and overcome resistance by breast cancer stem cells. J. Control. Release, 2015, 205, 7-14.
51. Naldi, I.; Taranta, M.; Gherardini, L.; Pelosi, G.; Viglione, F.; Grimaldi, S.; Pani, L.; Cinti, C. Novel epigenetic target therapy for prostate cancer: A preclinical study. PLoS One, 2014, 9, 98101.
52. Cinti, C.; Taranta, M.; Naldi, I.; Grimaldi, S. Newly engineered magnetic erythrocytes for sustained and targeted delivery of anticancer therapeutic compounds. PLoS One, 2011, 6, 17132.
53. Bu, Q.; Cui, L.; Li, J.; Du, X.; Zou, W.; Ding, K.; Pan, J. SAHA and S116836, a novel tyrosine kinase inhibitor, synergistically induce apoptosis in imatinib-resistant chronic myelogenous leukemia cells. Cancer Biol. Ther., 2014, 15, 951-962.
54. Ellinger, J.; Muller, S.C.; Dietrich, D. Epigenetic biomarkers in the blood of patients with urological malignancies. Expert Rev. Mol. Diagn., 2015, 15, 505-516.
55. Valdes-Mora, F.; Clark, S.J. Prostate cancer epigenetic biomarkers: Next-generation technologies. Oncogene, 2015, 34, 1609-1618.
56. Jurkowski, T.P.; Ravichandran, M.; Stepper, P. Synthetic epigenetics-towards intelligent control of epigenetic states and cell identity. Clin Epigenetics, 2015, 7, 18.
57. Falahi, F.; Sgro, A.; Blancafort, P. Epigenome engineering in cancer: Fairytale or a realistic path to the clinic? Front. Oncol., 2015, 5, 22.
58. Kasap, C.; Elemento, O.; Kapoor, T.M. Drug target seqR: A genomics- and CRISPR-Cas9-based method to analyze drug targets. Nat. Chem. Biol., 2014, 10, 626-628.
59. Hu, Z.; Ding, W.; Zhu, D.; Yu, L.; Jiang, X.; Wang, X.; Zhang, C.; Wang, L.; Ji, T.; Liu, D.; He, D.; Xia, X.; Zhu, T.; Wei, J.; Wu, P.; Wang, C.; Xi, L.; Gao, Q.; Chen, G.; Liu, R.; Li, K.; Li, S.; Wang, S.; Zhou, J.; Ma, D.; Wang, H. TALEN-mediated targeting of HPV oncogenes ameliorates HPV-related cervical malignancy. J. Clin. Invest., 2015, 125, 425-436.
60. Xiao, A.; Wu, Y.; Yang, Z.; Hu, Y.; Wang, W.; Zhang, Y.; Kong, L.; Gao, G.; Zhu, Z.; Lin, S.; Zhang, B. EENdb: A database and knowledge base of ZFNs and TALENs for endonuclease engineering. Nucleic Acids Res., 2013, 41, 415-422.
61. Fujita, T.; Fujii, H. Isolation of specific genomic regions and identification of associated molecules by engineered DNA-binding molecule-mediated chromatin immunoprecipitation (enChIP) using CRISPR. Methods Mol. Biol., 2015, 1288, 43-52.
62. Maeder, M.L.; Linder, S.J.; Cascio, V.M.; Fu, Y.; Ho, Q.H.; Joung, J.K. CRISPR RNA-guided activation of endogenous human genes. Nat. Methods, 2013, 10, 977-979.
63. Xue, W.; Chen, S.; Yin, H.; Tammela, T.; Papagiannakopoulos, T.; Joshi, N.S.; Cai, W.; Yang, G.; Bronson, R.; Crowley, D.G.; Zhang, F.; Anderson, D.G.; Sharp, P.A.; Jacks, T. CRISPRmediated direct mutation of cancer genes in the mouse liver. Nature, 2014, 514, 380-384.
64. Maddalo, D.; Manchado, E.; Concepcion, C.P.; Bonetti, C.; Vidigal, J.A.; Han, Y.C.; Ogrodowski, P.; Crippa, A.; Rekhtman, N.; de Stanchina, E.; Lowe, S.W.; Ventura, A. In vivo engineering of oncogenic chromosomal rearrangements with the CRISPR/Cas9 system. Nature, 2014, 516, 423-427.
65. Shalem, O.; Sanjana, N.E.; Hartenian, E.; Shi, X.; Scott, D.A.; Mikkelsen, T.S.; Heckl, D.; Ebert, B.L.; Root, D.E.; Doench, J.G.; Zhang, F. Genome-scale CRISPR-Cas9 knockout screening in human cells. Science (80)., 2014, 343, 84-87.
66. Liao, J.; Karnik, R.; Gu, H.; Ziller, M.J.; Clement, K.; Tsankov, A.M.; Akopian, V.; Gifford, C.A.; Donaghey, J.; Galonska, C.; Pop, R.; Reyon, D.; Tsai, S.Q.; Mallard, W.; Joung, J.K.; Rinn, J.L.; Gnirke, A.; Meissner, A. Targeted disruption of DNMT1, DNMT3A and DNMT3B in human embryonic stem cells. Nat. Genet., 2015, 47, 469-478.
67. Wen, W.S.; Yuan, Z.M.; Ma, S.J.; Xu, J.; Yuan, D.T. CRISPRCas9 systems: Versatile cancer modelling platforms and promising therapeutic strategies. Int. J. Cancer, 2016, 138, 1328-1336.
68. Konermann, S.; Brigham, M.D.; Trevino, A.E.; Joung, J.; Abudayyeh, O.O.; Barcena, C.; Hsu, P.D.; Habib, N.; Gootenberg, J.S.; Nishimasu, H.; Nureki, O.; Zhang, F. Genome-scale transcriptional activation by an engineered CRISPR-Cas9 Complex. Nature, 2015, 517, 583-588.
69. Waldrip, Z.J.; Byrum, S.D.; Storey, A.J.; Gao, J.; Byrd, A.K.; Mackintosh, S.G.; Wahls, W.P.; Taverna, S.D.; Raney, K.D.; Tackett, A.J. A CRISPR-based approach for proteomic analysis of a single genomic locus. Epigenetics, 2014, 9, 1207-1211.